ArticleEuropean journal of heart failure2016
Cell-based therapies for cardiac repair: a meeting report on scientific observations and European regulatory viewpoints.
Article in European journal of heart failure, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 33 citations in OpenAlex.
- Preclinical assessment for translation to humans: The PATH approach for assessing supporting evidence for early-phase trials and innovative care.Med (New York, N.Y.) · 2024Review
- Biologically Relevant Laminin-511 Moderates the Derivation and Proliferation of Human Lens Epithelial Stem/Progenitor-Like Cells.Investigative ophthalmology & visual science · 2024Article
- Pluripotent stem cell-derived committed cardiac progenitors remuscularize damaged ischemic hearts and improve their function in pigs.NPJ Regenerative medicine · 2023Article
- LRG1 promotes hypoxia-induced cardiomyocyte apoptosis and autophagy by regulating hypoxia-inducible factor-1α.Bioengineered · 2021Article
- New Strategies to Enhance Myocardial Regeneration: Expectations and Challenges from Preclinical Evidence.Current stem cell research & therapy · 2020Review
- Preclinical Development of Cell-Based Products: a European Regulatory Science Perspective.Pharmaceutical research · 2018Article
- Stem cell therapy for heart failure: Ensuring regenerative proficiency.Trends in cardiovascular medicine · 2016Review
- Clinical development plan for regenerative therapy in heart failure.European journal of heart failure · 2016Article
Corrections and comments
- Commented on by
Authors and funding
22 authors at 15 institutions in 18 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the past decade, novel cell-based products have been studied in patients with acute and chronic cardiac disease to assess whether these therapies are efficacious in improving heart function and preventing the development of end-stage heart failure. Cardiac indications studied include acute myocardial infarction (AMI), refractory angina, and chronic heart failure (CHF). Increased clinical activity, experience, and multiple challenges faced by developers have been recognized at the regulatory level. In May 2014, the Committee for Advanced Therapies (CAT) discussed in an expert meeting various cell-based medicinal products developed for cardiac repair, with a focus on non-manipulated bone marrow cells, sorted bone marrow or apheresis, and expanded cells, applied to patients with AMI or CHF. The intention was to share information, both scientific and regulatory, and to examine the challenges and opportunities in this field. These aspects were considered from the quality, and non-clinical and clinical perspectives, including current imaging techniques, with a focus on AMI and CHF. The scope of this overview is to present the European regulatory viewpoint on cell-based therapies for cardiac repair in the context of scientific observations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.